Scott Brun
- Virology top 0.5%
- HIV Research and Treatment 8
- Infectious Diseases top 1%
- HIV/AIDS drug development and treatment 14
- HIV/AIDS Research and Interventions 8
- Emergency Medicine top 2%
- HIV-related health complications and treatments 4
- Hepatology top 10%
- Ophthalmology top 5%
-
- CAR-T cell therapy research 3
- Cancer Immunotherapy and Biomarkers 3
-
- Immunotherapy and Immune Responses 3
-
- Pharmacological Effects and Toxicity Studies 3
Scott Brun
18 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 82
- Virology 933
- Infectious Diseases 1.2k
- Emergency Medicine 346
- Hepatology 97
- Ophthalmology 63
Countries citing papers authored by Scott Brun
This map shows the geographic impact of Scott Brun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Brun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Brun more than expected).
Fields of papers citing papers by Scott Brun
This network shows the impact of papers produced by Scott Brun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Brun. The network helps show where Scott Brun may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Scott Brun, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2023 | 4 | |
| 3 | 2022 | 8 | |
| 4 | 2007 | 10 | |
| 5 | 2007 | 17 | |
| 6 | 2006 | 2 | |
| 7 | 2005 | 22 | |
| 8 | 2005 | 70 | |
| 9 | 2004 | 172 | |
| 10 | 2004 | 58 | |
| 11 | 2003 | 75 | |
| 12 | Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infectionbreakdown → | 2002 | 518 |
| 13 | 2002 | 125 | |
| 14 | 2001 | 187 | |
| 15 | Kaletra (Lopinavir/ritonavir) Therapy in Single Protease Inhibitor Experienced Patients: 144-Week Follow-up | 2001 | 7 |
| 16 | Assessment of the pharmacokinetic interaction between ABT-378/ritonavir and efavirenz in healthy volunteers and in HIV + subjects | 2000 | 1 |
| 17 | Assessment of the pharmacokinetic interaction between lopinavir/ritonavir and nevirapine in HIV-infected pediatric subjects | 2000 | 1 |
| 18 | 1999 | 17 | |
| 19 | 1999 | 8 | |
| 20 | 1997 | 50 |
About Scott Brun
Scott Brun is a scholar working on Virology, Infectious Diseases, Emergency Medicine, Ophthalmology and Pediatrics, Perinatology and Child Health, having authored 20 papers that have together received 1.4k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (8 papers), HIV/AIDS Research and Interventions (8 papers), HIV-related health complications and treatments (4 papers), CAR-T cell therapy research (3 papers), Immunotherapy and Immune Responses (3 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Virology (933 citations), Infectious Diseases (1.2k citations), Emergency Medicine (346 citations), Hepatology (97 citations) and Ophthalmology (63 citations). Scott Brun has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Eugene Sun, Martin King, Barry Bernstein, Anthony J. Japour, Richard Lalonde, José Ramón Arribas, Gildon Beall, Sharon Walmsley, David W. Johnson and Peter Ruane. Their work appears in journals such as HIV Clinical Trials, The Journal of Infectious Diseases, Retina, Clinical Infectious Diseases and AIDS Patient Care and STDs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.